CIPROFLOXACIN IN RESPIRATORY-TRACT INFECTIONS - A PHASE-IV SURVEILLANCE STUDY

Ciprofloxacin was investigated in bacterial respiratory tract infections in an open multicenter study with 122 physicians. Treatment was assessed according to subjective and objective clinical symptoms. There were 683 patients in the trial. The dosage was 250 mg BID or 500 mg BID of ciprofloxacin, depending on the severity of the infection. The average duration of treatment was 9 days. The clinical assessment of ciprofloxacin treatment showed cure in 537 patients (78.6%) and improvement in 132 patients (19.3%). Only 14 patients (2.0%) were assessed as treatment failures, Adverse events, primarily gastrointestinal in nature, occurred in 12 patients; 13 of these patients (1.9%) discontinued treatment. The study results support the clinical efficacy of ciprofloxacin in the outpatient management of lower and upper respiratory tract infections. In addition, the safety of ciprofloxacin in general medical practice was substantiated.